Building regulated biomedical ventures from science to scale.
We transform high-potential biomedical technologies into structured, investable and scalable ventures by integrating science, regulatory architecture, manufacturing, clinical execution and capital formation.
Breakthrough science is not enough.
Ownership, regulation, manufacturing, clinical evidence, governance and capital formation are systematically fragmented. Most high-potential biomedical technologies never reach patients — not for lack of science, but for lack of architecture.
Systematically fragmented
- 01Ownership & Equity Structure
- 02Regulatory Architecture
- 03Manufacturing Readiness
- 04Clinical Evidence
- 05Corporate Governance
- 06Capital Formation
We do not simply support ventures. We architect them.
Logos integrates equity structure, IP ownership, regulatory strategy, manufacturing readiness, clinical development and capital formation into a single coherent architecture — from the first scientific assessment to commercial scale.
One architecture. Five critical stages.
Discover
Scientific and commercial assessment of the technology opportunity
Architect
Structural design of equity, IP, regulatory and development pathways
Validate
Technical, regulatory and market validation of the venture thesis
Build
Execution of manufacturing, clinical, corporate and capital milestones
Scale
Commercial expansion, international partnerships and long-term value capture
Value is designed, not added at the end.
CURRENT PROGRAMS
Portfolio
View all programsCAR-T Mexico
National CAR-T CD19 therapy platform developed through international technology transfer, CMC/GMP manufacturing, clinical validation and institutional access in Mexico.
Under Development — No Clinical Availability
CellBilden
Precision-health platform connecting multidimensional biological assessment, functional data and scientifically grounded intervention pathways.
Under Development — No Clinical Availability
SpineForce
Early-stage biomedical engineering program under scientific, technical and commercial definition.
Under Development — No Clinical Availability
MyoPatch
Early-stage biomedical engineering program under scientific, technical and commercial definition.
Under Development — No Clinical Availability
One Architecture. Multiple Critical Capabilities.
Scientific and Product Strategy
Rigorous assessment of scientific merit, product definition and development feasibility from first principles.
Regulatory, Quality and CMC Architecture
Integrated regulatory strategy, quality systems design and chemistry, manufacturing and controls planning.
Clinical Development
Structured clinical program design, protocol development and evidence generation aligned with regulatory requirements.
Venture and Corporate Architecture
Equity structuring, IP ownership, corporate formation and governance design for investable, scalable ventures.
Business Development and Capital
Strategic partnerships, licensing, technology transfer and capital formation across international markets.
Intellectual Assets and Long-Term Value
IP strategy, data rights, licensing architectures and royalty structures designed for durable competitive advantage.
Certain capabilities are delivered through Axiom Biostrategy, a specialized secondary capability of Logos Bioscience.
Global science. Regional execution. International value.
Different partners. One aligned development architecture.
Explore PartnershipsStart here
Start with the opportunity.
We will examine the architecture.
Whether you hold a scientific asset, a development mandate or a capital thesis — the conversation begins with the opportunity.